{"disease":{"id":"who-grade-2-glioma","name":"who grade 2 glioma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04576117","title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04166409","title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03243461","title":"International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":167,"lead_sponsor_name":"University of Göttingen","has_results":false},{"nct_id":"NCT07389278","title":"Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":97,"lead_sponsor_name":"Sabine Mueller, MD, PhD","has_results":false},{"nct_id":"NCT03212274","title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":89,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06410248","title":"Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05859334","title":"Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06964737","title":"Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04284774","title":"Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04650204","title":"Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT04195555","title":"Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04320888","title":"Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}